Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Jeff P. Sharman

1Willamette Valley Cancer Institute, Sarah Cannon Research, Eugene, OR

Talha Munir

12St. James's University Hospital, Department of Haematology, Leeds, United Kingdom

Sebastian Grosicki

Department of Cancer Prevention, Medical University of Silesia, Katowice, Poland

Lindsey E. Roeker

15Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY

John M. Burke

4Rocky Mountain Cancer Centers, US Oncology Research, Aurora, CO

Christine I. Chen

Norbert Grzasko

George Follows

14Department of Haematology, Addenbrooke’s Hospital NHS Trust, Cambridge, United Kingdom

Zoltan Matrai

Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary

Alessandro Sanna

41Hematology Unit, AOU Careggi, University of Florence, Florence, Italy

Lugui Qiu

Ru Feng

Vu Minh Hua

12Liverpool Hospital, New South Wales, Australia

Wojciech Jurczak

Matthias Ritgen

Universitaetsklinikum Schleswig-Holstein, Medizinische Klinik II, Kiel, Germany

Shuhua Yi

4State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

Francesc Bosch

Department of Hematology, University Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Barcelona

Catherine C. Coombs

University of California Irvine, Irvine, CA

Katherine Bao

15Eli Lilly and Company, Indianapolis, United States

Vishalkumar Patel

4Eli Lilly and Company, Indianapolis, United States

Bin Liu

Livia Compte

Ananya Guntur

3Eli Lilly and Company, Indianapolis, United States

Denise Y. Wang

Jeff P. Sharman, MD, Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR; Bin Liu, MSc, MPH, Denise Y. Wang, PhD, and Ching Ching Leow, PhD Eli Lilly and Company, Indianapolis, IN; and Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

Marisa Hill

21Eli Lilly and Company, Indianapolis, United States

Ching Ching Leow

21Eli Lilly and Company, Indianapolis, United States

Paolo Ghia

School of Medicine, Università Vita Salute San Raffaele, Milan

Paul M. Barr